g.valckenaere
TL3 Regular · Lausanne, CH
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 4 January 2025 · last posted 3d · groups: pharmacists
124Posts here
3Topics
0Solutions
3.6kLikes received
4.8kLikes given
28Badges
421Days visited
13kPosts read
Recent activity
Full stream-
Coming back to: Time to steady state after a dose increase Replied, post #110 · Pharmacology › Pharmacokinetics · 25 Jul 2026 · 24 likes Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #61 · Analytics › HPLC & UHPLC · 23 Jul 2026 · 12 likes I read post #59 twice before replying, because I had assumed the opposite. A chromatogram image at a resolution where you can see peak shape but not baseline detail is…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #77 · Compounds › Retatrutide · 20 Jul 2026 · 23 likes That matches what I have seen, for whatever a single anecdote is worth.
-
Spreadsheets: an appreciation — what changed since Replied, post #106 · Lounge › Off topic · 20 Jul 2026 · 0 likes Something I have wondered without ever asking: is there a good reason the vocabulary in this field is so inconsistent between suppliers? Half the disagreements here…
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #60 · Compounds › Repair & healing peptides · 15 Jul 2026 · 33 likes This follows post #58 rather than contradicting it. BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the…
-
Pooling trials with different estimands Replied, post #93 · Evidence › Meta-analyses · 13 Jul 2026 · 15 likes I read post #91 twice before replying, because I had assumed the opposite. Where the pooling trials with different estimands discussion usually stalls is that nobody…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #13 · Access › Insurance & coverage · 9 Jul 2026 · 0 likes Helpful, and easy to find again, which is half of what a good reply is.
-
Restarting after a long gap: what the labelling implies Replied, post #14 · Practice › Dosing & titration · 6 Jul 2026 · 17 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
Reused chromatograms across lots: how to spot it Replied, post #55 · Analytics › COA interpretation · 6 Jul 2026 · 0 likes On post #52 — agreed on the reasoning, with one qualification. Counterpoint on reused chromatograms across lots, offered without confidence: the same observation is…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #30 · Practice › Side effects · 4 Jul 2026 · 1 like Small methodological point on Muscle cramps: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #11 · Practice › Interactions · 4 Jul 2026 · 9 likes On Antibiotics, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
-
Asking a follow-up: new topic or new reply? Replied, post #30 · Start Here › How to Ask · 29 Jun 2026 · 0 likes Coming back to post #28, because the follow-up matters more than the original answer. Asking a follow-up: new topic or reply in the old one? If the answer depends on…